APACT Trial in Pancreatic Adenocarcinoma

APACT Trial in Pancreatic Adenocarcinoma

obr

1 year
155 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Leonard Saltz, MD, Executive Director for Clinical Value and Sustainability, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center shares the results from the APACT study, a phase III trial involving adjuvant nab-paclitaxel plus gemcitabine versus gemcitabine alone for surgically resected pancreatic adenocarcinoma.
Up Next Autoplay